| Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European … O Penack, M Marchetti, T Ruutu, M Aljurf, A Bacigalupo, F Bonifazi, ... The Lancet Haematology 7 (2), e157-e167, 2020 | 421 | 2020 |
| Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious … D Averbuch, G Tridello, J Hoek, M Mikulska, H Akan, ... Clinical Infectious Diseases 65 (11), 1819-1828, 2017 | 221 | 2017 |
| Prognostic Significance of the Cell Cycle Inhibitor p27Kip1 in Chronic B-Cell Lymphocytic Leukemia R Vrhovac, A Delmer, R Tang, JP Marie, R Zittoun, ... Blood, The Journal of the American Society of Hematology 91 (12), 4694-4700, 1998 | 221 | 1998 |
| Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the … PJ Hayden, C Roddie, P Bader, GW Basak, H Bonig, C Bonini, ... Annals of Oncology 33 (3), 259-275, 2022 | 190 | 2022 |
| The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma LE Toner, R Vrhovac, EA Smith, J Gardner, M Heaney, M Gonen, ... Clinical cancer research 12 (3), 924-932, 2006 | 84 | 2006 |
| Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind … HP Erba, P Montesinos, HJ Kim, E Patkowska, R Vrhovac, P Žák, ... The Lancet 401 (10388), 1571-1583, 2023 | 77 | 2023 |
| More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML) R Kusec, O Jaksic, S Ostojic, I Kardum-Skelin, R Vrhovac, B Jaksic Blood 108 (1), 405-406, 2006 | 74 | 2006 |
| Role of angiogenesis in chronic lymphocytic leukemia T Letilovic, R Vrhovac, S Verstovsek, B Jaksic, A Ferrajoli Cancer: Interdisciplinary International Journal of the American Cancer …, 2006 | 69 | 2006 |
| Ruxolitinib for the treatment of myelofibrosis: its clinical potential A Ostojic, R Vrhovac, S Verstovsek Therapeutics and Clinical Risk Management, 95-103, 2012 | 65 | 2012 |
| Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis A Ostojic, R Vrhovac, S Verstovsek Future oncology 7 (9), 1035-1043, 2011 | 65 | 2011 |
| Cyclin D1 overexpression allows identification of an aggressive subset of leukemic lymphoproliferative disorder V Levy, V Ugo, A Delmer, R Tang, S Ramond, JY Perrot, R Vrhovac, ... Leukemia 13 (9), 1343-1351, 1999 | 50 | 1999 |
| Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies … N Polverelli, K Mauff, N Kröger, M Robin, D Beelen, D Beauvais, ... American journal of hematology 96 (1), 69-79, 2021 | 49 | 2021 |
| Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects H Akan, VP Antia, M Kouba, J Sinko, AD Tănase, R Vrhovac, R Herbrecht Journal of antimicrobial chemotherapy 68 (suppl_3), iii5-iii16, 2013 | 48 | 2013 |
| Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation … R Vrhovac, M Labopin, F Ciceri, J Finke, E Holler, J Tischer, B Lioure, ... Bone marrow transplantation 51 (2), 186-193, 2016 | 47 | 2016 |
| Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen, J Passweg, ... Leukemia 35 (12), 3551-3560, 2021 | 46 | 2021 |
| Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics D Radić-Krišto, A Planinc-Peraica, S Ostojić, R Vrhovac, I Kardum-Skelin, ... Collegium antropologicum 34 (2), 413-417, 2010 | 43 | 2010 |
| A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia M Kalac, A Quintás‐Cardama, R Vrhovac, H Kantarjian, S Verstovsek Cancer 110 (5), 955-964, 2007 | 42 | 2007 |
| Early human cytomegalovirus reactivation is associated with lower incidence of relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation Z Peric, J Wilson, N Durakovic, A Ostojic, L Desnica, VR Vranjes, ... Bone Marrow Transplantation 53 (11), 1450-1456, 2018 | 40 | 2018 |
| Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors J Randhawa, A Ostojic, R Vrhovac, E Atallah, S Verstovsek Journal of Hematology & Oncology 5, 1-7, 2012 | 39 | 2012 |
| S100: quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly … H Erba, P Montesinos, R Vrhovac, E Patkowska, HJ Kim, P Zak, PN Wang, ... HemaSphere 6, 1-2, 2022 | 35 | 2022 |
